Swedish Orphan Biovitrum AB (B6E.SG)
| Previous Close | 21.11 |
| Open | 21.19 |
| Bid | 21.37 x 100000 |
| Ask | 21.58 x 100000 |
| Day's Range | 21.19 - 21.35 |
| 52 Week Range | 18.08 - 22.91 |
| Volume | |
| Avg. Volume | 3 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
- GlobeNewswire
Sobi Receives Approval from Health Canada for Empaveli™ (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria
The first targeted C3 therapy approved in CanadaApproval based on results from head-to-head PEGASUS phase 3 study where Empaveli™ demonstrated superiority to eculizumab in improving hemoglobin levels1On trial, transfusion avoidance was achieved by 85.4% patients in the Empaveli group versus 15.4% in the eculizumab group1 WALTHAM, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), announced today that Health
- Reuters
UPDATE 2-U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients
Sobi North America, a unit of Swedish Orphan Biovitrum AB, said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. The drug, already approved in the European Union for treating COVID, has been authorized in the United States to treat patients with pneumonia who require oxygen support and those at risk of developing severe respiratory failure. The authorization of Sobi's Kineret adds another option for COVID treatment in the United States, as the disease moves from a pandemic to an endemic stage.
